453 related articles for article (PubMed ID: 30683036)
1. [Multilocus sequence analysis, biofilm production, antibiotic susceptibility and synergy tests of Burkholderia species in patients with and without cystic fibrosis].
Akışoğlu Ö; Engin D; Sarıçam S; Müştak HK; Şener B; Hasçelik G
Mikrobiyol Bul; 2019 Jan; 53(1):22-36. PubMed ID: 30683036
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients.
Kenna DTD; Lilley D; Coward A; Martin K; Perry C; Pike R; Hill R; Turton JF
J Med Microbiol; 2017 Apr; 66(4):490-501. PubMed ID: 28463663
[TBL] [Abstract][Full Text] [Related]
3. Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis.
Medina-Pascual MJ; Valdezate S; Carrasco G; Villalón P; Garrido N; Saéz-Nieto JA
Clin Microbiol Infect; 2015 Feb; 21(2):150-6. PubMed ID: 25658563
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of bacteraemia caused by Burkholderia cepacia complex species and antimicrobial susceptibility of the isolates in a medical centre in Taiwan.
Chien YC; Liao CH; Sheng WH; Chien JY; Huang YT; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2018 Mar; 51(3):357-364. PubMed ID: 28705667
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients.
Díez-Aguilar M; Ekkelenkamp M; Morosini MI; Merino I; de Dios Caballero J; Jones M; van Westreenen M; Tunney MM; Cantón R; Fluit AC
Int J Antimicrob Agents; 2019 Jan; 53(1):84-88. PubMed ID: 30240837
[TBL] [Abstract][Full Text] [Related]
6. Clonality and Antimicrobial Susceptibility of Burkholderia cepacia complex Isolates Collected from Cystic Fibrosis Patients during 1998-2013 in Bern, Switzerland.
Lupo A; Isis E; Tinguely R; Endimiani A
New Microbiol; 2015 Apr; 38(2):281-8. PubMed ID: 25938755
[TBL] [Abstract][Full Text] [Related]
7. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
[TBL] [Abstract][Full Text] [Related]
8. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Burkholderia cepacia complex species in cystic fibrosis patients in Argentina during the period 2011-2015.
Cipolla L; Rocca F; Martinez C; Aguerre L; Barrios R; Prieto M
Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(7):431-434. PubMed ID: 29055510
[TBL] [Abstract][Full Text] [Related]
10. Matrix-assisted laser desorption/ionization time-of-flight MS for the accurate identification of
Wong KSK; Dhaliwal S; Bilawka J; Srigley JA; Champagne S; Romney MG; Tilley P; Sadarangani M; Zlosnik JEA; Chilvers MA
J Med Microbiol; 2020 Aug; 69(8):1105-1113. PubMed ID: 32597748
[No Abstract] [Full Text] [Related]
11.
Narayanaswamy VP; Duncan AP; LiPuma JJ; Wiesmann WP; Baker SM; Townsend SM
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910901
[No Abstract] [Full Text] [Related]
12. Rapid emergence of a ceftazidime-resistant Burkholderia multivorans strain in a cystic fibrosis patient.
Stokell JR; Gharaibeh RZ; Steck TR
J Cyst Fibros; 2013 Dec; 12(6):812-6. PubMed ID: 23478130
[TBL] [Abstract][Full Text] [Related]
13. Combination antimicrobial susceptibility testing of Burkholderia cepacia complex: significance of species.
Abbott FK; Milne KE; Stead DA; Gould IM
Int J Antimicrob Agents; 2016 Nov; 48(5):521-527. PubMed ID: 27665523
[TBL] [Abstract][Full Text] [Related]
14. Use of matrix assisted laser desorption ionisation-time of flight mass spectrometry in a paediatric clinical laboratory for identification of bacteria commonly isolated from cystic fibrosis patients.
Desai AP; Stanley T; Atuan M; McKey J; Lipuma JJ; Rogers B; Jerris R
J Clin Pathol; 2012 Sep; 65(9):835-8. PubMed ID: 22639406
[TBL] [Abstract][Full Text] [Related]
15. Burkholderia puraquae sp. nov., a novel species of the Burkholderia cepacia complex isolated from hospital settings and agricultural soils.
Martina P; Leguizamon M; Prieto CI; Sousa SA; Montanaro P; Draghi WO; Stämmler M; Bettiol M; de Carvalho CCCR; Palau J; Figoli C; Alvarez F; Benetti S; Lejona S; Vescina C; Ferreras J; Lasch P; Lagares A; Zorreguieta A; Leitão JH; Yantorno OM; Bosch A
Int J Syst Evol Microbiol; 2018 Jan; 68(1):14-20. PubMed ID: 29095137
[TBL] [Abstract][Full Text] [Related]
16. Novel
Steyaert S; Peeters C; Wieme AD; Muyldermans A; Vandoorslaer K; Spilker T; Wybo I; Piérard D; LiPuma JJ; Vandamme P
Microbiol Spectr; 2024 Jun; 12(6):e0402123. PubMed ID: 38661349
[TBL] [Abstract][Full Text] [Related]
17. Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry: rapid identification of bacteria isolated from patients with cystic fibrosis.
Baillie S; Ireland K; Warwick S; Wareham D; Wilks M
Br J Biomed Sci; 2013; 70(4):144-8. PubMed ID: 24400425
[TBL] [Abstract][Full Text] [Related]
18. Fourier Transform Infrared Spectroscopy for Typing Burkholderia cenocepacia ET12 Isolates.
Barker KR; Santino M; LiPuma JJ; Tullis E; Muller MP; Matukas LM; Tadros M
Microbiol Spectr; 2021 Dec; 9(3):e0183121. PubMed ID: 34878338
[TBL] [Abstract][Full Text] [Related]
19. Polyphasic characterisation of Burkholderia cepaciacomplex species isolated from children with cystic fibrosis.
Vicenzi FJ; Pillonetto M; Souza HA; Palmeiro JK; Riedi CA; Rosario-Filho NA; Dalla-Costa LM
Mem Inst Oswaldo Cruz; 2016 Jan; 111(1):37-42. PubMed ID: 26814642
[TBL] [Abstract][Full Text] [Related]
20. Antibiofilm and antimicrobial activity of curcumin-chitosan nanocomplexes and trimethoprim-sulfamethoxazole on
Montoya-Hinojosa EI; Salazar-Sesatty HA; Alvizo-Baez CA; Terrazas-Armendariz LD; Luna-Cruz IE; Alcocer-González JM; Villarreal-Treviño L; Flores-Treviño S
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):213-223. PubMed ID: 36625029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
